{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:18:44Z","timestamp":1790165924679,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T00:00:00Z","timestamp":1500940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100008799","name":"Stiftung f\u00fcr Pathobiochemie und Molekulare Diagnostik","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008799","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10238-017-0468-z","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T01:47:09Z","timestamp":1500947229000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Circulating fibroblast growth factor 21 in patients with liver cirrhosis"],"prefix":"10.1007","volume":"18","author":[{"given":"Sabrina","family":"Krautbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rein-Fischboeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M","family":"Haberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Wiest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-3994","authenticated-orcid":false,"given":"Christa","family":"Buechler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"468_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217\u201331. doi: 10.1016\/j.jhep.2005.10.013 .","journal-title":"J Hepatol"},{"key":"468_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMra1504367","volume":"375","author":"PS Ge","year":"2016","unstructured":"Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375:767\u201377. doi: 10.1056\/NEJMra1504367 .","journal-title":"N Engl J Med"},{"key":"468_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12769","author":"H Kawaratani","year":"2016","unstructured":"Kawaratani H, Fukui H, Yoshiji H. Treatment for cirrhotic ascites. Hepatol Res. 2016;. doi: 10.1111\/hepr.12769 .","journal-title":"Hepatol Res"},{"key":"468_CR4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/hep.1840190312","volume":"19","author":"AS Petrides","year":"1994","unstructured":"Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology. 1994;19:616\u201327.","journal-title":"Hepatology"},{"key":"468_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12787","volume":"1353","author":"RM Carr","year":"2015","unstructured":"Carr RM, Correnti J. Insulin resistance in clinical and experimental alcoholic liver disease. Ann N Y Acad Sci. 2015;1353:1\u201320. doi: 10.1111\/nyas.12787 .","journal-title":"Ann N Y Acad Sci"},{"key":"468_CR6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/MEG.0000000000000627","volume":"28","author":"D Degre","year":"2016","unstructured":"Degre D, Gustot T, Gerkens A, et al. Insulin resistance is associated with esophageal varices in alcoholic liver disease patients. Eur J Gastroenterol Hepatol. 2016;28:792\u20136. doi: 10.1097\/MEG.0000000000000627 .","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"468_CR7","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3748\/wjg.v17.i23.2801","volume":"17","author":"C Buechler","year":"2011","unstructured":"Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011;17:2801\u201311. doi: 10.3748\/wjg.v17.i23.2801 .","journal-title":"World J Gastroenterol"},{"key":"468_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nm.2277","volume":"17","author":"WL Holland","year":"2011","unstructured":"Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17:55\u201363. doi: 10.1038\/nm.2277 .","journal-title":"Nat Med"},{"key":"468_CR9","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1665-2681(19)31343-2","volume":"12","author":"M Eslam","year":"2013","unstructured":"Eslam M, Ampuero J, Jover M, et al. Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. Ann Hepatol. 2013;12:588\u201398.","journal-title":"Ann Hepatol"},{"key":"468_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1440-1746.2006.04757.x","volume":"23","author":"S Kakizaki","year":"2008","unstructured":"Kakizaki S, Sohara N, Yamazaki Y, et al. Elevated plasma resistin concentrations in patients with liver cirrhosis. J Gastroenterol Hepatol. 2008;23:73\u20137. doi: 10.1111\/j.1440-1746.2006.04757.x .","journal-title":"J Gastroenterol Hepatol"},{"key":"468_CR11","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3748\/wjg.v21.i10.3020","volume":"21","author":"M Kalafateli","year":"2015","unstructured":"Kalafateli M, Triantos C, Tsochatzis E, et al. Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol. 2015;21:3020\u20139. doi: 10.3748\/wjg.v21.i10.3020 .","journal-title":"World J Gastroenterol"},{"key":"468_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2796.2005.01543.x","volume":"258","author":"S Kaser","year":"2005","unstructured":"Kaser S, Moschen A, Kaser A, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med. 2005;258:274\u201380. doi: 10.1111\/j.1365-2796.2005.01543.x .","journal-title":"J Intern Med"},{"key":"468_CR13","doi-asserted-by":"publisher","first-page":"148526","DOI":"10.1155\/2013\/148526","volume":"2013","author":"B Kasztelan-Szczerbinska","year":"2013","unstructured":"Kasztelan-Szczerbinska B, Surdacka A, Slomka M, et al. Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease. Mediat Inflamm. 2013;2013:148526. doi: 10.1155\/2013\/148526 .","journal-title":"Mediat Inflamm"},{"key":"468_CR14","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.2337\/db08-1750","volume":"58","author":"N Halberg","year":"2009","unstructured":"Halberg N, Schraw TD, Wang ZV, et al. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes. 2009;58:1961\u201370. doi: 10.2337\/db08-1750 .","journal-title":"Diabetes"},{"key":"468_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.metabol.2009.09.011","volume":"59","author":"R Wiest","year":"2010","unstructured":"Wiest R, Moleda L, Farkas S, et al. Splanchnic concentrations and postprandial release of visceral adipokines. Metabolism. 2010;59:664\u201370. doi: 10.1016\/j.metabol.2009.09.011 .","journal-title":"Metabolism"},{"key":"468_CR16","doi-asserted-by":"publisher","first-page":"E82","DOI":"10.1152\/ajpendo.00494.2003","volume":"287","author":"UJ Tietge","year":"2004","unstructured":"Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab. 2004;287:E82\u20139. doi: 10.1152\/ajpendo.00494.2003 .","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"468_CR17","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/j.1478-3231.2011.02498.x","volume":"31","author":"J Dasarathy","year":"2011","unstructured":"Dasarathy J, Alkhouri N, Dasarathy S. Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature. Liv Int. 2011;31:1250\u20138. doi: 10.1111\/j.1478-3231.2011.02498.x .","journal-title":"Liv Int"},{"key":"468_CR18","doi-asserted-by":"publisher","first-page":"G486","DOI":"10.1152\/ajpgi.00375.2009","volume":"299","author":"P Holland-Fischer","year":"2010","unstructured":"Holland-Fischer P, Nielsen MF, Vilstrup H, et al. Insulin sensitivity and body composition in cirrhosis: changes after TIPS. Am J Physiol Gastrointest Liv Physiol. 2010;299:G486\u201393. doi: 10.1152\/ajpgi.00375.2009 .","journal-title":"Am J Physiol Gastrointest Liv Physiol"},{"key":"468_CR19","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.clnu.2012.04.001","volume":"31","author":"KL Thomsen","year":"2012","unstructured":"Thomsen KL, Sandahl TD, Holland-Fischer P, et al. Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism. Clin Nutr. 2012;31:940\u20135. doi: 10.1016\/j.clnu.2012.04.001 .","journal-title":"Clin Nutr"},{"key":"468_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1124\/mol.108.044826","volume":"74","author":"ES Muise","year":"2008","unstructured":"Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol. 2008;74:403\u201312. doi: 10.1124\/mol.108.044826 .","journal-title":"Mol Pharmacol"},{"key":"468_CR21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","volume":"1492","author":"T Nishimura","year":"2000","unstructured":"Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492:203\u20136.","journal-title":"Biochim Biophys Acta"},{"key":"468_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250\u20139. doi: 10.2337\/db08-0392 .","journal-title":"Diabetes"},{"key":"468_CR23","doi-asserted-by":"publisher","first-page":"13479","DOI":"10.1038\/ncomms13479","volume":"7","author":"T Quesada-Lopez","year":"2016","unstructured":"Quesada-Lopez T, Cereijo R, Turatsinze JV, et al. The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes. Nat Commun. 2016;7:13479. doi: 10.1038\/ncomms13479 .","journal-title":"Nat Commun"},{"key":"468_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","volume":"17","author":"Z Lin","year":"2013","unstructured":"Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17:779\u201389. doi: 10.1016\/j.cmet.2013.04.005 .","journal-title":"Cell Metab"},{"key":"468_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.taap.2014.04.013","volume":"278","author":"X Cheng","year":"2014","unstructured":"Cheng X, Vispute SG, Liu J, et al. Fibroblast growth factor (Fgf) 21 is a novel target gene of the aryl hydrocarbon receptor (AhR). Toxicol Appl Pharmacol. 2014;278:65\u201371. doi: 10.1016\/j.taap.2014.04.013 .","journal-title":"Toxicol Appl Pharmacol"},{"key":"468_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-230X-13-67","volume":"13","author":"C Yang","year":"2013","unstructured":"Yang C, Lu W, Lin T, et al. Activation of liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol. 2013;13:67. doi: 10.1186\/1471-230X-13-67 .","journal-title":"BMC Gastroenterol"},{"issue":"1073\u201383","key":"468_CR27","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1053\/j.gastro.2014.07.044","volume":"147","author":"FM Fisher","year":"2014","unstructured":"Fisher FM, Chui PC, Nasser IA, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology. 2014;147(1073\u201383):e6. doi: 10.1053\/j.gastro.2014.07.044 .","journal-title":"Gastroenterology"},{"key":"468_CR28","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/gut.2009.193227","volume":"59","author":"M Rossle","year":"2010","unstructured":"Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988\u20131000. doi: 10.1136\/gut.2009.193227 .","journal-title":"Gut"},{"key":"468_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.regpep.2012.08.007","volume":"179","author":"S Bauer","year":"2012","unstructured":"Bauer S, Eisinger K, Wiest R, et al. Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury. Regul Pept. 2012;179:10\u20134. doi: 10.1016\/j.regpep.2012.08.007 .","journal-title":"Regul Pept"},{"key":"468_CR30","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/eci.12122","volume":"43","author":"K Eisinger","year":"2013","unstructured":"Eisinger K, Krautbauer S, Wiest R, et al. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur J Clin Invest. 2013;43:926\u201332. doi: 10.1111\/eci.12122 .","journal-title":"Eur J Clin Invest"},{"key":"468_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.yexmp.2015.01.010","volume":"98","author":"K Eisinger","year":"2015","unstructured":"Eisinger K, Krautbauer S, Wiest R, Weiss TS, Buechler C. Reduced serum chemerin in patients with more severe liver cirrhosis. Exp Mol Pathol. 2015;98:208\u201313. doi: 10.1016\/j.yexmp.2015.01.010 .","journal-title":"Exp Mol Pathol"},{"key":"468_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cyto.2011.06.001","volume":"55","author":"J Wanninger","year":"2011","unstructured":"Wanninger J, Weigert J, Wiest R, et al. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine. 2011;55:435\u201340. doi: 10.1016\/j.cyto.2011.06.001 .","journal-title":"Cytokine"},{"key":"468_CR33","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1365-2265.2009.03664.x","volume":"72","author":"J Weigert","year":"2010","unstructured":"Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010;72:342\u20138. doi: 10.1111\/j.1365-2265.2009.03664.x .","journal-title":"Clin Endocrinol (Oxf)"},{"key":"468_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.diabres.2014.01.003","volume":"104","author":"H Ahmadieh","year":"2014","unstructured":"Ahmadieh H, Azar ST. Liver disease and diabetes: association, pathophysiology, and management. Diabetes Res Clin Pract. 2014;104:53\u201362. doi: 10.1016\/j.diabres.2014.01.003 .","journal-title":"Diabetes Res Clin Pract"},{"key":"468_CR35","first-page":"309","volume":"57","author":"V Goral","year":"2010","unstructured":"Goral V, Atalay R, Kucukoner M. Insulin resistance in liver cirrhosis. Hepatogastroenterology. 2010;57:309\u201315.","journal-title":"Hepatogastroenterology"},{"issue":"Suppl 2","key":"468_CR36","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1055\/s-0042-115159","volume":"11","author":"D M\u00fcller-Wieland","year":"2016","unstructured":"M\u00fcller-Wieland D, Petermann A, Nauck M, Heinemann L, Kerner W, M\u00fcller UA, Landgraf R. Definition, klassifikation und diagnostik des diabetes mellitus. Diabetologie. 2016;11(Suppl 2):S78\u201381. doi: 10.1055\/s-0042-115159 (\u00a9 Georg Thieme Verlag KG Stuttgart, New York, 2016).","journal-title":"Diabetologie"},{"key":"468_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000444556","volume":"34","author":"R Weiskirchen","year":"2016","unstructured":"Weiskirchen R, Tacke F. Liver fibrosis: from pathogenesis to novel therapies. Dig Dis. 2016;34:410\u201322. doi: 10.1159\/000444556 .","journal-title":"Dig Dis"},{"key":"468_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4093\/dmj.2013.37.6.404","volume":"37","author":"HK Park","year":"2013","unstructured":"Park HK, Ahima RS. Resistin in rodents and humans. Diabetes Metab J. 2013;37:404\u201314. doi: 10.4093\/dmj.2013.37.6.404 .","journal-title":"Diabetes Metab J"},{"key":"468_CR39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.biotechadv.2015.12.010","volume":"34","author":"SK Vashist","year":"2015","unstructured":"Vashist SK, Venkatesh AG, Marion Schneider E, et al. Bioanalytical advances in assays for C-reactive protein. Biotechnol Adv. 2015;34:272\u201390. doi: 10.1016\/j.biotechadv.2015.12.010 .","journal-title":"Biotechnol Adv"},{"key":"468_CR40","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/MEG.0b013e32835fd699","volume":"25","author":"F Ucar","year":"2013","unstructured":"Ucar F, Sezer S, Ginis Z, et al. APRI, the FIB-4 score, and Forn\u2019s index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2013;25:1076\u201381. doi: 10.1097\/MEG.0b013e32835fd699 .","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"468_CR41","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3109\/00365521.2012.694901","volume":"47","author":"M Kukla","year":"2012","unstructured":"Kukla M, Berdowska A, Stygar D, et al. Serum FGF21 and RBP4 levels in patients with chronic hepatitis C. Scand J Gastroenterol. 2012;47:1037\u201347. doi: 10.3109\/00365521.2012.694901 .","journal-title":"Scand J Gastroenterol"},{"key":"468_CR42","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","volume":"53","author":"H Li","year":"2010","unstructured":"Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53:934\u201340. doi: 10.1016\/j.jhep.2010.05.018 .","journal-title":"J Hepatol"},{"key":"468_CR43","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.2337\/dc09-0684","volume":"32","author":"AO Chavez","year":"2009","unstructured":"Chavez AO, Molina-Carrion M, Abdul-Ghani MA, et al. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32:1542\u20136. doi: 10.2337\/dc09-0684 .","journal-title":"Diabetes Care"},{"key":"468_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/cen.12134","volume":"80","author":"Y Lee","year":"2014","unstructured":"Lee Y, Lim S, Hong ES, et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf). 2014;80:57\u201364. doi: 10.1111\/cen.12134 .","journal-title":"Clin Endocrinol (Oxf)"},{"key":"468_CR45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s12072-010-9216-0","volume":"4","author":"TA Salman","year":"2010","unstructured":"Salman TA, Allam N, Azab GI, et al. Study of adiponectin in chronic liver disease and cholestasis. Hepatol Int. 2010;4:767\u201374. doi: 10.1007\/s12072-010-9216-0 .","journal-title":"Hepatol Int"},{"key":"468_CR46","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/cen.12380","volume":"80","author":"J Hindricks","year":"2014","unstructured":"Hindricks J, Ebert T, Bachmann A, et al. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol (Oxf). 2014;80:918\u201324. doi: 10.1111\/cen.12380 .","journal-title":"Clin Endocrinol (Oxf)"},{"key":"468_CR47","doi-asserted-by":"publisher","first-page":"e18398","DOI":"10.1371\/journal.pone.0018398","volume":"6","author":"Z Lin","year":"2011","unstructured":"Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE. 2011;6:e18398. doi: 10.1371\/journal.pone.0018398 .","journal-title":"PLoS ONE"},{"key":"468_CR48","first-page":"50","volume":"61","author":"B Matuszek","year":"2010","unstructured":"Matuszek B, Lenart-Lipinska M, Duma D, Solski J, Nowakowski A. Evaluation of concentrations of FGF-21\u2014a new adipocytokine in type 2 diabetes. Endokrynol Pol. 2010;61:50\u20134.","journal-title":"Endokrynol Pol"},{"key":"468_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.diabres.2011.02.034","volume":"93","author":"X Li","year":"2011","unstructured":"Li X, Fan X, Ren F, et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract. 2011;93:10\u20136. doi: 10.1016\/j.diabres.2011.02.034 .","journal-title":"Diabetes Res Clin Pract"},{"key":"468_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/eci.12695","volume":"47","author":"R Pohl","year":"2017","unstructured":"Pohl R, Haberl EM, Rein-Fischboeck L, et al. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. Eur J Clin Invest. 2017;47:7\u201318. doi: 10.1111\/eci.12695 .","journal-title":"Eur J Clin Invest"},{"key":"468_CR51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/13813455.2016.1212898","volume":"122","author":"L Berti","year":"2016","unstructured":"Berti L, Hartwig S, Irmler M, et al. Impact of fibroblast growth factor 21 on the secretome of human perivascular preadipocytes and adipocytes: a targeted proteomics approach. Arch Physiol Biochem. 2016;122:281\u20138. doi: 10.1080\/13813455.2016.1212898 .","journal-title":"Arch Physiol Biochem"},{"key":"468_CR52","doi-asserted-by":"publisher","first-page":"11294","DOI":"10.3390\/ijms150711294","volume":"15","author":"K Imai","year":"2014","unstructured":"Imai K, Takai K, Hanai T, et al. Impact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma. Int J Mol Sci. 2014;15:11294\u2013306. doi: 10.3390\/ijms150711294 .","journal-title":"Int J Mol Sci"},{"key":"468_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cyto.2012.03.030","volume":"59","author":"B Sun","year":"2012","unstructured":"Sun B, Yang G, Yang M, et al. Long-term high-fat diet links the regulation of the insulin-sensitizing fibroblast growth factor-21 and visfatin. Cytokine. 2012;59:131\u20137. doi: 10.1016\/j.cyto.2012.03.030 .","journal-title":"Cytokine"},{"key":"468_CR54","first-page":"669","volume":"45","author":"M Gudowska","year":"2015","unstructured":"Gudowska M, Gruszewska E, Cylwik B, et al. Galectin-3 concentration in liver diseases. Ann Clin Lab Sci. 2015;45:669\u201373.","journal-title":"Ann Clin Lab Sci"},{"key":"468_CR55","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1572-0241.2006.00543.x","volume":"101","author":"E Yagmur","year":"2006","unstructured":"Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol. 2006;101:1244\u201352. doi: 10.1111\/j.1572-0241.2006.00543.x .","journal-title":"Am J Gastroenterol"},{"key":"468_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1471-230X-11-107","volume":"11","author":"D Benten","year":"2011","unstructured":"Benten D, Schulze zur Wiesch J, Sydow K, et al. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS). BMC Gastroenterol. 2011;11:107. doi: 10.1186\/1471-230X-11-107 .","journal-title":"BMC Gastroenterol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-017-0468-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-017-0468-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-017-0468-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T10:58:59Z","timestamp":1569927539000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-017-0468-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1007\/s10238-017-0468-z","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,25]]}}}